Chikungunya and zika virus Vaccines

Stefan W. Metz, Gorben P. Pijlman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The spread of chikungunya and Zika viruses can be controlled by vaccination of human populations. Classical inactivated virus formulations and live attenuated viruses have demonstrated different rates of success. The molecular toolbox is now advanced enough to explore the potential of novel vaccine modalities that are in different stages of development and (pre)clinical testing. Here, we describe the state of the art of classical and next-generation vaccine platforms including viral vectored and chimeric vaccines, virus-like particles (VLPs), and nucleic acid (DNA, RNA), and subunit vaccines. We review their development, characterization, immunogenicity, and safety and we provide a future outlook for these vaccines to alleviate the burden of disease in areas where mosquitoes continue to spread these pathogens. Finally, we indicate particular challenges for chikungunya and Zika vaccines to proceed though clinical trials and become commercially available.

Original languageEnglish
Title of host publicationChikungunya and Zika Viruses
Subtitle of host publicationGlobal Emerging Health Threats
EditorsS. Higgs, D.L. Vanlandingham, A.M. Powers
PublisherElsevier
Chapter11
Pages347-365
Number of pages19
ISBN (Electronic)9780128118658
ISBN (Print)9780128118665
DOIs
Publication statusPublished - 1 Aug 2018

Keywords

  • Animal models
  • Arbovirus
  • Chikungunya
  • Clinical trials
  • Immunity
  • Mosquito
  • Vaccines
  • Zika

Fingerprint Dive into the research topics of 'Chikungunya and zika virus Vaccines'. Together they form a unique fingerprint.

Cite this